Issue link: https://www.e-digitaleditions.com/i/807837
ExciPact publishes 2017 draft revision of GMP, GDP standards BRUSSELS, Belgium—ExciPact published a 2017 draft revision of its GMP and GDP standards to align with ISO 9001:2015 and ISO/IEC 17021-1:2015. The documents are used in the group's independent, third- party international certification of manufacturers, suppliers, and distribu- tors of excipients. Interested parties can comment on the draft revision until May 5. NSF, IDMA offer pharma quality management program BANGALORE, India— NSF Inter- national, Ann Arbor, MI, and the Indian Drug Manufacturers' Assoc- iation (IDMA) are offering courses on pharmaceutical quality management at Acharya College, located here. Professionals who complete the full program earn a certification in GMP compliance. The program comprises five modules, each lasting 4 days, that can be completed in 10 months, with modules offered every other month. Classes are slated to start in September. Briefly noted… The FDA approved Celegene's Revlimid (lenalidomide) as mainte- nance therapy for patients with mul- tiple myeloma following autologous stem cell transplant. The FDA approved Odactra, the first allergen extract administered as a sublingual tablet to treat house dust mite-induced nasal inflammation, with or without eye inflammation. The once-daily treatment is meant to be taken year-round by patients age 18 to 65. It is manufactured by Merck, Sharpe & Dohme. 10 April 2017 Tablets & Capsules